Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor

  • The Company’s anti-cancer drug – (CPL304110) – might be indicated for patients with lung, bladder and stomach tumours which have genetic aberrations of FGFR kinases.
  • The objective of the trial will be to determine the drug’s safety profile (including MTD) and observation of early symptoms of drug activity in the trial subjects.
  • The clinical trial will be held in Poland; the study design was developed and verified in cooperation with key clinicians and toxicologists from Poland, Belgium, Great Britain and the USA.
  • The Company has also developed its own modern diagnostic tests which will be used to select patients for the first phase of the trial, scheduled to take several months.

Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: This is a very important stage for us, we have been preparing for it over the course of several years. We are facing a significant and uneasy challenge, which is the result of i.a. the study design itself and the specific characteristics of patients enrolled in the trial. That is why the trial is implemented in cooperation with key scientific centres in Poland.